AfaSci, Inc., a San Francisco Bay Area biotech, has been developing two therapeutic candidates with backup compounds for the treatment of neuropathic pain and neuroinflammatory pain. Both analgesic candidates are non-opioid, non-addictive and non-steroidal analgesics. US patents on both new classes of drugs were granted and PCT in 17 other nations are in processing. Furthermore, our pipeline includes new chemical entities with novel mechanisms of action for treatments of Alzheimer’s disease, epilepsy and sleep disorders. Our competitive advantage includes our drug candidates ready for IND-enabling studies, proprietary drug discovery platform that are all reviewed and supported by NIH grants. AfaSci has a strong research team and excellent facility in-house including well-established electrophysiology and in vivo pharmacology. AfaSci received approval of NIH OLAW Assurance and established an IACUC for conducting animal research.
AfaSci, Inc. is presenting as part of the NIH Innovation Zone.